ILC Dover LP, Newark, plans to break ground on a new 90,000 sq ft manufacturing site located in Gliwice, Poland.
Gliwice is a university and industrial city in southern Polland.
in response to continued growth within its life sciences business. The facility equipped with 20,000 square feet of cleanroom capability will manufacture initially single-use powder bags, single-use liquid bags, and single-use fluid transfer assemblies.
The new site will provide redundant supply capabilities and reduce the lead times for its European and Asian customers. Manufacturing will be consistent with the Company’s global quality system.
The new site follows the company’s recent announcement to expand production capabilities in its existing Mexico facility in response to growth and its entry into new biotherapeutic markets. Biotherapeutics use substances made from living organisms to treat disease
This expansion, in addition to the new facility in Poland, is the latest investment ILC Dover has made to advance its life sciences products for a global customer base, including biotherapeutic, cell & gene therapy, and pharmaceutical markets. The new facility in Poland is scheduled to come online in early 2023.
The facility will be home to 250 employees at full capacity – joining ILC Dover’s 2,000-plus employees worldwide. The company’s current global biopharmaceutical manufacturing footprint in Juarez, Mexico, Frederica DE, Durham, NC, Stockport UK, Rossens, Switzerland, and Blarney, Ireland.
“We are very excited to expand our global footprint in Poland with a new manufacturing facility equipped with the capacity to better serve our growing European and APAC customer base,” said Corey Walker, CEO of ILC Dover. “Providing critical solutions to the world’s leading life sciences customers remains top priority as our strategic investments center around ways to improve and optimize their workflows.”
